The Displacement Effect: How Section 232 Pharma Tariffs Will Deepen the Capacity Crisis for the Modalities They Exempt

On April 2, 2026, the White House imposed 100% tariffs on patented pharmaceutical products and ingredients under Section 232 of the Trade Expansion Act.

The policy included a set of deliberate carve-outs. Nuclear medicines, cell and gene therapies, antibody-drug conjugates, orphan drugs, plasma-derived therapies, and medical countermeasures were all exempted at 0%.

On paper, the most complex and supply-constrained modalities in the industry are protected.

In practice, the exemption protects the molecule. It does not protect the manufacturing system the molecule depends on.

This article maps the second-order effects of the tariff-driven onshoring wave on the CDMO infrastructure, talent supply, and scheduling dynamics that exempt modality programmes rely on.

The Tariff Architecture

The Section 232 Proclamation creates a tiered system, not a flat rate.

The baseline is 100% on patented drugs and associated ingredients. For companies listed in Annex III of the Proclamation (17 of the largest multinationals, including Lilly, Pfizer, J&J, Novartis, and AstraZeneca), tariffs take effect on July 31, 2026. A 120-day window. For smaller companies, the deadline extends to September 29, 2026. 180 days.

Companies that commit to onshoring manufacturing can access a reduced 20% tariff. Companies that sign both onshoring agreements with the Department of Commerce and Most-Favoured-Nation pricing agreements with HHS can reach 0%, valid through January 20, 2029.

Products from allied trade-deal countries face capped rates. EU, Japan, South Korea, and Switzerland at 15%. The UK at 10%.

Generics and biosimilars are exempt for now, with a reassessment mandated by April 2027.

The result is a massive financial forcing function. Every major pharma company with imported branded products now faces a binary choice: absorb a 100% margin hit, or commit capital to domestic manufacturing.

$480 billion in investment commitments followed within weeks. At least 22 new manufacturing sites were announced. An estimated 44,000 new jobs created.

The Timeline Mismatch

Those numbers sound like a solution. They are not.

Commissioning, Qualification, and Validation (CQV) for a new sterile fill-finish facility takes a minimum of 4 to 7 years. Equipment procurement alone (isolators, RABS, lyophilisers) carries 12 to 24-month lead times. Physical construction takes another 18 to 36 months. Then the facility must complete Installation, Operational, and Performance Qualification. Then mandatory aseptic process simulations (media fills). Then regulatory approval.

Eli Lilly's sterile injectable facility in Lehigh Valley, Pennsylvania begins construction in 2026. It will not be operational until 2031. Their Huntsville, Alabama API facility targets 2032.

Zero net-new greenfield capacity comes online before 2029.

The 120-day tariff window is a negotiation deadline, not a construction timeline. It is designed to extract investment commitments and pricing concessions. The administration's own tariff architecture acknowledges this through its 20% transitional rate, which escalates to 100% over four years if onshoring milestones are not met.

But the immediate consequence is clear. 100% of the onshoring demand triggered by these tariffs is crashing into existing US CDMO networks. Today.

Where the Infrastructure Is Shared

The assumption underlying the exemption is that exempt and non-exempt modalities occupy separate manufacturing ecosystems.

They do not.

Modern CDMOs are built around multi-product, multi-modality facilities designed for maximum asset utilisation. The same sterile fill-finish lines, cleanroom suites, QA/QC teams, and analytical release labs that serve standard branded biologics also serve exempt therapies.

The sharing is specific and well-documented.

Thermo Fisher Scientific (Greenville, North Carolina) operates what is arguably the highest-throughput sterile drug product hub in the US CDMO market. The site added four high-speed pre-filled syringe lines in 2025. It currently fills an estimated 70 million vials per year of Novo Nordisk's GLP-1 franchise (Ozempic, Wegovy) on the same aseptic suites capable of servicing exempt sterile biologics.

Lonza (Portsmouth, New Hampshire) runs a dedicated 12,000 square metre allogeneic cell therapy facility for Vertex (exempt) directly adjacent to its standard mammalian Phase 3 and commercial biologics suites (non-exempt). Both rely on the same shared campus-wide QA, environmental monitoring, and QC release labs.

Resilience (Cincinnati, Ohio) is investing over $225 million to target the GLP-1 market across four high-speed fill lines. The same lines also service advanced gene therapy products. The company's own materials confirm the site serves "multiple modalities and therapeutic indications, including GLP-1."

Grand River Aseptic Manufacturing (Grand Rapids, Michigan) operates five independent filling lines using SKAN isolator technology. The same stainless-steel machinery toggles between standard biologics (non-exempt) and vaccines (exempt) via Single-Use Technology changeouts and VHP decontamination cycles.

Fujifilm Biotechnologies (Holly Springs, North Carolina) opened a $3.2 billion cell culture facility in September 2025. Regeneron signed a 10-year, $3 billion manufacturing agreement. Johnson & Johnson secured $2 billion in capacity. When fill-finish capabilities come online in 2026, this facility will serve both large-scale mAb programmes (non-exempt) and potentially exempt modalities, sharing QA/QC infrastructure across both.

The pattern is consistent across the US CDMO network. The exempt and non-exempt labels exist in the tariff code. They do not exist on the manufacturing floor.

The Displacement Mechanism

CDMO scheduling logic is commercially rational.

A standard branded biologic campaign might run 150,000 units on a continuous, multi-week production schedule. The filling line runs predictably. Changeover is minimal. Revenue per line-hour is high.

An orphan drug or highly potent ADC might run 5,000 units. The batch requires extensive VHP decontamination between campaigns, specialised containment protocols, and a full SUT changeout. Revenue per line-hour is a fraction of the branded biologic.

When every major pharma company is simultaneously bidding for US-based fill-finish slots to avoid a 100% tariff, CDMOs will prioritise the blockbuster contract. Every time. This is not a failure of ethics. It is the straightforward economics of asset utilisation in a seller's market.

The result is a cascading displacement of exempt modality programmes.

Three Second-Order Effects

1. Fill-finish lead times for exempt programmes are stretching

Before April 2, 2026, sterile fill-finish was already the most capacity-constrained segment of the outsourcing market. Industry benchmarking had established, for four consecutive years, that on-time delivery and capacity availability surpassed cost as the primary CDMO selection criteria for sterile and biologics sponsors.

The Novo Holdings acquisition of Catalent in late 2024, and the subsequent $11 billion transfer of three premier fill-finish sites (Bloomington, Brussels, Anagni) to Novo Nordisk for captive GLP-1 production, permanently removed some of the most capable sterile capacity from the open CDMO market before the tariff wave even hit.

Post-Proclamation, exempt modality sponsors are reporting fill-finish lead times stretching from 6 to 8 months toward 18 to 24 months. Decade-long, multi-billion-dollar take-or-pay contracts from Regeneron, J&J, and others are locking up entire manufacturing suites at the major CDMO sites. Smaller exempt-modality sponsors, typically clinical-stage biotechs without the balance sheet to secure block-booked capacity, are being pushed to the back of the queue.

2. QA/QC team saturation is becoming the binding constraint

Even where an exempt programme secures physical time on a filling line, batch release can stall.

QA/QC teams at multi-product CDMOs are matrixed. A shared QC microbiology team handles environmental monitoring across all cleanrooms regardless of the modality being processed. Shared analytical chemistry teams perform raw material release testing and final product validation for both standard biologics and exempt therapies.

The onboarding of massive onshoring contracts requires intense analytical validation, technology transfer documentation, supplier change notifications, and continuous environmental monitoring. CDMO leadership will inevitably dedicate their top QA/QC personnel to ensuring compliance and rapid release for multi-billion-dollar Big Pharma accounts.

This reallocation deprioritises the complex, time-consuming analytical reviews required for niche CGT or ADC programmes. Batches get manufactured. Then they sit in QC quarantine.

The talent arithmetic makes this worse, not better. The biologics sector currently has approximately 60,000 unfilled positions against an employed workforce of just 46,000. CQV engineers are operating at a 3:1 demand-to-supply ratio. The FDA issued 112 cGMP warning letters in FY2025, the highest in more than two decades, with 99% citing documentation errors and procedural failures directly attributable to overworked QA staff. The workforce required to absorb the onshoring wave does not exist at current scale.

3. The CGT overcapacity paradox

This finding is counterintuitive but structurally important.

The cell and gene therapy CDMO sector entered 2026 in overcapacity at the upstream level. Construction between 2019 and 2024 outpaced active clinical trials by more than two-to-one. Catalent cut over 400 jobs at its Maryland gene therapy operations in 2025 and closed its Gosselies cell therapy site in January 2026. Resilience shuttered six of its ten sites.

CGT drug substance (upstream viral vector manufacturing) has surplus capacity.

CGT drug product fill-finish does not.

Because downstream fill-finish shares infrastructure with standard branded biologics, it sits in the same queue as every non-exempt programme now competing for US slots. Exempt modality sponsors seeking fill-finish face the same capacity crunch as non-exempt sponsors. The tariff exemption does not distinguish between upstream and downstream. The manufacturing floor does.

Radiopharma: Structurally Insulated, Not Immune

Nuclear medicines occupy a genuinely separate manufacturing sub-sector. Their infrastructure - lead-lined hot cells, isotope-handling licences, automated radiation handling, and compressed release-to-ship timelines driven by isotope half-lives - is physically incompatible with standard sterile fill-finish operations.

A branded biologic and a lutetium-177 therapy will never compete for the same isolator line. The physics won't allow it. This makes radiopharma the one exempt modality that is structurally insulated from direct line displacement.

But insulation is not immunity.

Shared QC laboratories, analytical testing personnel, and batch release functions at multi-service CDMO campuses remain indirect bottlenecks. When the analytical team at a campus that houses both a hot cell suite and a standard fill-finish line is consumed by onshoring tech transfers for non-exempt branded drugs, the radiopharma programme feels the drag at the release stage, not the production stage.

The displacement is indirect. But it is real.

The Orphan Drug Trap

One additional structural risk deserves attention.

The Section 232 specialty exemption for orphan drugs applies only where all approved indications carry orphan designation under the Orphan Drug Act. This is a deliberately narrow gate.

Mid-cap sponsors that successfully pursue label expansions into non-orphan indications will lose their 0% exemption. The drug moves from exempt to non-exempt, and the company faces the full tariff structure.

This creates a perverse incentive where commercial success (expanding into larger patient populations) triggers a financial penalty (loss of tariff exemption) that was not modelled at the point of investment.

Companies and investors underwriting orphan drug programmes should model this explicitly.

What This Means

The Section 232 tariffs achieved exactly what they intended. They will force domestic manufacturing of branded drugs. The $480 billion in commitments is real, even if the construction timelines extend to 2030 and beyond.

But the policy design does not account for the shared infrastructure problem. It assumes that exempting a product category is the same as protecting the manufacturing system that category depends on. It is not.

For sponsors of exempt modalities, the practical implications are immediate:

CDMO engagement lead times that were 6 to 8 months pre-Proclamation should now be treated as 12 to 18 months minimum.

QA/QC bandwidth, not line time, is likely to be the binding constraint through at least 2028.

Radiopharma programmes are insulated from line competition but exposed at the analytical layer.

ADC programmes face the highest direct displacement risk, because high-containment filling suites required for cytotoxic payloads are also sought for high-potency non-exempt branded oncology drugs.

The orphan drug all-indications requirement is a genuine commercial planning risk for any programme considering label expansion.

The capacity crisis for exempt modalities was already structural. The onshoring stampede has made it worse.

Byron Fitzgerald is the Founder of ProGen Search, a retained executive search and market intelligence firm serving life sciences, radiopharma, CDMO, ADC, and cell and gene therapy. ProGen publishes intelligence reports including The State of Radiopharmaceuticals 2026, The Isotope Production Map Q2 2026, and Weaponised Capacity: The CDMO Intelligence Report.